Fig. 3 From: Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical studyMean central subfield thickness (CSFT) during the 24-week follow-up period. *Indicates statistically significant change compared to baseline (p < 0.05). There was significant improvement at all follow-up visits when compared to baselineBack to article page